ClinicalTrials.gg
CompletedNCT04421027COV-BARRIERUpdated Jul 28, 2022Results posted

A Study of Baricitinib (LY3009104) in Participants With COVID-19

A Phase 3 interventional study of Baricitinib and Placebo in COVID-19, sponsored by Eli Lilly and Company. Completed at 96 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,525
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing baricitinib in COVID-19 — 3 open to participants now, 4 under way, 3 of them phase 3. baricitinib · COVID-19.

Enrollment
3rd of 20
1,525 · median 184
Started
2020
with 12 others
Phase 3
9 of 20
3 open now
Registered
11th of 20
by date
Lead sponsor
2 of 20
Eli Lilly and Company

Among the 20 studies testing baricitinib in COVID-19, this one is the 3rd largest by enrollment, is one of 13 that started in 2020, is one of 9 in phase 3, and was the 11th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 20 studies testing baricitinib in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing baricitinib in COVID-19, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

03

Conditions studied

  • COVID-19

Keywords

  • coronavirus
  • coronavirus infection
  • safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by polymerase chain reaction (PCR) test or other commercial or public health assay in any specimen, as documented by either of the following:

    • PCR positive in sample collected \<72 hours prior to randomization; OR
    • PCR positive in sample collected ≥72 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.
  • Requires supplemental oxygen at the time of study entry and at randomization.
  • Have indicators of risk of progression: at least 1 inflammatory markers > (ULN) (C reactive protein [CRP], D dimer, lactate dehydrogenase [LDH], ferritin) with at least 1 instance of elevation >ULN within 2 days before study entry.

Exclusion criteria

Exclusion Criteria:

  • Are receiving cytotoxic or biologic treatments (such as tumor necrosis factor [TNF] inhibitors, anti-interleukin-1 [IL-1], anti-IL-6 [tocilizumab or sarilumab], T-cell or B-cell targeted therapies (rituximab), interferon, or Janus kinase (JAK) inhibitors for any indication at study entry. Note: A 4 weeks (or 5 half-lives, whichever is longer) is required prior to screening.
  • Have ever received convalescent plasma or intravenous immunoglobulin [IVIg]) for COVID-19.
  • Have received high dose at doses >20 mg per day (or prednisone equivalent) administered for ≥14 consecutive days in the month prior to study entry.
  • Strong inhibitors of OAT3 (such as probenecid) that cannot be discontinued at study entry.
  • Have received neutralizing antibodies, such as bamlanivimab, casirivimab and imdevimab for COVID-19.
  • Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required).
  • Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking product.
  • Have received any within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of nonlive (inactivated) vaccinations is allowed for all participants.
  • Require invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry.
  • Current diagnosis of active that, in the opinion of the investigator, could constitute a risk when taking investigational product.
  • Have a history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]) within 12 weeks prior to randomization or have a history of recurrent (>1) VTE (DVT/PE).
  • Anticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry.
  • Have neutropenia ( \<1000 cells/microliters).
  • Have lymphopenia (absolute lymphocyte count \<200 cells/microliters).
  • Have (ALT) or aspartate aminotransferase (AST) >5 times .
  • Estimated (eGFR) (Modification of Diet in Renal Disease [MDRD]) \<30 milliliter/minute/1.73 meters squared.
  • Have a known to baricitinib or any of its .
  • Are currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (started) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28.
  • Are pregnant, or intend to become pregnant or breastfeed during the study.
  • Are using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb®.
  • Are, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,525 participants (actual)

Study arms

  • Experimental
    Baricitinib + Standard of Care (SOC)

    4 milligrams (mg) of baricitinib (given as two 2 mg tablets) administered orally every day (QD) with standard of care.

    Drug: Baricitinib

  • Placebo comparator
    Placebo + SOC

    Placebo (given as two placebo tablets) administered orally QD with standard of care.

    Drug: Placebo

Interventions

  • Given orally

    Also known as: LY3009104

  • DrugPlacebo

    Given orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])

    Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO).

    Time frame: Day 1 to Day 28

  2. Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2

    Percentage of participants who die or require non-invasive ventilation or invasive mechanical ventilation, including ECMO.

    Time frame: Day 1 to Day 28

Secondary outcomes

  1. Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital

    The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Participants with missing baseline ordinal scale values were excluded from analysis.

    Time frame: Day 10

  2. Number of Ventilator-Free Days

    Number of days free of invasive mechanical ventilation.

    Time frame: Day 1 to Day 28

  3. Time to Recovery

    Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day. NIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)

    Time frame: Day 1 to Day 28

  4. Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4

    Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

    Time frame: Day 4

  5. Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7

    Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

    Time frame: Day 7

  6. Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10

    Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

    Time frame: Day 10

  7. Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14

    Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

    Time frame: Day 14

  8. Duration of Hospitalization

    Duration of hospitalization.

    Time frame: Days 1 to Day 28

  9. Percentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline

    Percentage of participants with a change in oxygen saturation from \< 94% to ≥ 94% from baseline based on National Early Warning Score (NEWS). Measure of the oxygen level of the blood is measure by pulse oximetry. The score is determined from six physiological parameters readily measured over time in hospitalized participants: Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness, as measured by Alert Voice Pain Unresponsive (AVPU). A score is assigned to each parameter, the magnitude of the score representing the extremity of variation from the norm. A weighting score is added for participants needing supplemental oxygen (oxygen delivery by mask or by cannula) The aggregate score is reflective of the participants status.

    Time frame: Day 10

  10. Overall Mortality

    Number of deaths by Day 28.

    Time frame: Day 1 to Day 28

  11. Duration of Stay in the Intensive Care Unit (ICU) in Days

    Duration of stay in the ICU in days.

    Time frame: Day 1 to Day 28

  12. Time to Clinical Deterioration (One-category Increase on the NIAID-OS)

    The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. A higher score is representative of worse clinical outcome with a score of 8 being the highest and representing death.

    Time frame: Day 1 to Day 28

  13. Time to Resolution of Fever in Participants With Fever at Baseline

    Time to resolution of fever in participants with fever at baseline was calculated using cox proportional hazard regression model adjusted for baseline disease severity (OS 4, OS 5, OS 6), age (\<65 years, \>=65 years), region (United States, Europe, rest of world), and systemic corticosteroids used at baseline for primary study condition (Yes/No).

    Time frame: Day 1 to Day 28

  14. Mean Change From Baseline on the National Early Warning Score (NEWS)

    The NEWS score is used to detect and report changes in illness severity in participants with acute illness to identify participants at risk for poor outcomes. The score is based on six physiological parameters (Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness). A score is assigned to each parameter, and the sum of the score represents the participant's risk of poor outcomes with a minimum score of 0 representing the better outcome, a score of 7 or greater reflects high clinical risk for worsening and maximum score of 19 representing the worse outcome.

    Time frame: Baseline, Day 4; Baseline, Day 7; Baseline, Day 10; Baseline, Day 14

  15. Time to Definitive Extubation

    Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.

    Time frame: Day 1 to Day 28

  16. Time to Independence From Non-Invasive Mechanical Ventilation

    Time to independence from non-invasive mechanical ventilation was measured in days among participants who required non-invasive ventilation.

    Time frame: Day 1 to Day 28

  17. Time to Independence From Oxygen Therapy in Days

    Time to independence from oxygen therapy in days.

    Time frame: Day 1 to Day 28

  18. Number of Days With Supplemental Oxygen Use

    Number of days with supplemental oxygen use.

    Time frame: Day 1 to Day 28

  19. Number of Days of Resting Respiratory Rate <24 Breaths Per Minute

    Number of days of resting respiratory rate \<24 breaths per minute.

    Time frame: Day 1 to Day 28

07

Results

Posted Mar 24, 2022

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlacebo + Standard of Care (SOC)Baricitinib + SOCPlacebo + SOC Follow-UpBaricitinib + SOC Follow-Up
Started76176400
Received at least one dose of study drug75275000
Completed60464400
Not completed15712000
Withdrew: Adverse event5300
Withdrew: Death986100
Withdrew: Lost to follow-up222000
Withdrew: Other-unknown15900
Withdrew: Physician decision1100
Withdrew: Withdrawal by subject71200
Withdrew: Randomized not dosed91400
Follow-Up Period
Participant flow — Follow-Up Period
MilestonePlacebo + Standard of Care (SOC)Baricitinib + SOCPlacebo + SOC Follow-UpBaricitinib + SOC Follow-Up
Started00613645
Completed00588615
Not completed002530
Withdrew: Adverse event0003
Withdrew: Death001617
Withdrew: Lost to follow-up0077
Withdrew: Protocol deviation0010
Withdrew: Still in hospital on ventilator at end of study0010
Withdrew: Left message, participant did not call back0001
Withdrew: Participant died0001
Withdrew: Participant was alive but did not respond to calls0001

Outcome measures

PrimaryPercentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])

Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO).

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])
percentage of participantsPlacebo + SOCBaricitinib + SOC
Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])30.5 (27.2 to 33.8)27.8 (24.6 to 31.0)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Regression, Logistic · p = 0.1800 · Odds ratio (or): 0.85 · 95% CI 0.67 to 1.08
PrimaryPercentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2

Percentage of participants who die or require non-invasive ventilation or invasive mechanical ventilation, including ECMO.

Time frame:
Day 1 to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2
percentage of participantsPlacebo + SOCBaricitinib + SOC
Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 227.1 (18.7 to 35.6)28.9 (19.6 to 38.2)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Regression, Logistic · p = 0.7280 · Odds ratio (or): 1.12 · 95% CI 0.58 to 2.16
SecondaryPercentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital

The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Participants with missing baseline ordinal scale values were excluded from analysis.

Time frame:
Day 10
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital
percentage of participantsPlacebo + SOCBaricitinib + SOC
Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital63.5 (60.1 to 67.0)65.0 (61.6 to 68.5)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Regression, Logistic · p = 0.5444 · Odds ratio (or): 1.07 · 95% CI 0.86 to 1.34
SecondaryNumber of Ventilator-Free Days

Number of days free of invasive mechanical ventilation.

Time frame:
Day 1 to Day 28
Reported as:
Least squares mean · days
Number of Ventilator-Free Days
daysPlacebo + SOCBaricitinib + SOC
Number of Ventilator-Free Days23.7 ± 0.3924.5 ± 0.39
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · ANOVA · p = 0.0586 · Ls mean difference (net): 0.75 · 95% CI -0.0 to 1.5
SecondaryTime to Recovery

Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day. NIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)

Time frame:
Day 1 to Day 28
Reported as:
Median · days
Time to Recovery
daysPlacebo + SOCBaricitinib + SOC
Time to Recovery11.0 (10.0 to 12.0)10.0 (9.0 to 11.0)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Log Rank · p = 0.1453 · Hazard ratio (hr): 1.11 · 95% CI 0.99 to 1.24
SecondaryPercentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4

Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

Time frame:
Day 4
Reported as:
Number · percentage of participants
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4
percentage of participantsPlacebo + SOCBaricitinib + SOC
Day 4 NIAID-OS 14.6 (3.1 to 6.1)5.2 (3.6 to 6.8)
Day 4 NIAID-OS 21.5 (0.6 to 2.4)1.5 (0.6 to 2.4)
Day 4 NIAID-OS 30.8 (0.2 to 1.4)0.3 (0.0 to 0.7)
Day 4 NIAID-OS 419.4 (16.6 to 22.3)23.6 (20.6 to 26.7)
Day 4 NIAID-OS 541.0 (37.5 to 44.5)39.0 (35.5 to 42.5)
Day 4 NIAID-OS 622.4 (19.5 to 25.4)21.8 (18.9 to 24.8)
Day 4 NIAID-OS 78.9 (6.8 to 10.9)8.1 (6.2 to 10.1)
Day 4 NIAID-OS 81.4 (0.5 to 2.2)0.4 (0.0 to 0.9)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Proportional Odds Model · p = 0.0464 · Odds ratio (or): 1.21 · 95% CI 1.00 to 1.47
SecondaryPercentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7

Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

Time frame:
Day 7
Reported as:
Number · percentage of participants
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7
percentage of participantsPlacebo + SOCBaricitinib + SOC
Day 7 NIAID-OS 120.2 (17.3 to 23.1)25.2 (22.1 to 28.4)
Day 7 NIAID-OS 26.6 (4.8 to 8.4)5.8 (4.1 to 7.5)
Day 7 NIAID-OS 30.5 (0.0 to 1.1)0.2 (0.0 to 0.5)
Day 7 NIAID-OS 421.2 (18.2 to 24.1)20.6 (17.6 to 23.5)
Day 7 NIAID-OS 522.5 (19.5 to 25.5)22.5 (19.4 to 25.5)
Day 7 NIAID-OS 614.5 (12.0 to 17.0)13.8 (11.3 to 16.2)
Day 7 NIAID-OS 711.2 (9.0 to 13.5)10.8 (8.6 to 13.0)
Day 7 NIAID-OS 83.3 (2.0 to 4.5)1.2 (0.4 to 2.0)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Proportional Odds Model · p = 0.0172 · Odds ratio (or): 1.25 · 95% CI 1.04 to 1.49
SecondaryPercentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10

Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

Time frame:
Day 10
Reported as:
Number · percentage of participants
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10
percentage of participantsPlacebo + SOCBaricitinib + SOC
Day 10 NIAID-OS 137.7 (34.2 to 41.2)40.4 (36.9 to 44.0)
Day 10 NIAID-OS 29.4 (7.3 to 11.5)10.9 (8.7 to 13.2)
Day 10 NIAID-OS 30.1 (0.0 to 0.4)0.1 (0.0 to 0.4)
Day 10 NIAID-OS 416.2 (13.6 to 18.9)14.1 (11.6 to 16.6)
Day 10 NIAID-OS 512.8 (10.3 to 15.2)12.4 (10.0 to 14.8)
Day 10 NIAID-OS 68.1 (6.1 to 10.0)8.9 (6.8 to 11.0)
Day 10 NIAID-OS 710.6 (8.4 to 12.9)10.4 (8.2 to 12.6)
Day 10 NIAID-OS 85.1 (3.5 to 6.7)2.6 (1.5 to 3.8)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Proportional Odds Model · p = 0.0921 · Odds ratio (or): 1.17 · 95% CI 0.97 to 1.41
SecondaryPercentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14

Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14
percentage of participantsPlacebo + SOCBaricitinib + SOC
Day 14 NIAID-OS 151.6 (48.0 to 55.2)56.3 (52.7 to 59.9)
Day 14 NIAID-OS 211.2 (8.9 to 13.5)11.1 (8.8 to 13.4)
Day 14 NIAID-OS 30.3 (0.0 to 0.6)0.1 (0.0 to 0.4)
Day 14 NIAID-OS 48.0 (6.0 to 10.0)7.6 (5.7 to 9.6)
Day 14 NIAID-OS 58.4 (6.4 to 10.5)7.3 (5.4 to 9.2)
Day 14 NIAID-OS 63.6 (2.2 to 4.9)3.7 (2.3 to 5.1)
Day 14 NIAID-OS 79.4 (7.3 to 11.6)8.9 (6.9 to 11.0)
Day 14 NIAID-OS 87.5 (5.6 to 9.4)4.9 (3.4 to 6.5)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Proportional Odds Model · p = 0.0168 · Odds ratio (or): 1.28 · 95% CI 1.05 to 1.56
SecondaryDuration of Hospitalization

Duration of hospitalization.

Time frame:
Days 1 to Day 28
Reported as:
Least squares mean · days
Duration of Hospitalization
daysPlacebo + SOCBaricitinib + SOC
Duration of Hospitalization13.7 ± 0.4012.9 ± 0.40
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · ANOVA · p = 0.0626 · Ls mean difference (net): -0.76 · 95% CI -1.6 to 0.0
SecondaryPercentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline

Percentage of participants with a change in oxygen saturation from \< 94% to ≥ 94% from baseline based on National Early Warning Score (NEWS). Measure of the oxygen level of the blood is measure by pulse oximetry. The score is determined from six physiological parameters readily measured over time in hospitalized participants: Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness, as measured by Alert Voice Pain Unresponsive (AVPU). A score is assigned to each parameter, the magnitude of the score representing the extremity of variation from the norm. A weighting score is added for participants needing supplemental oxygen (oxygen delivery by mask or by cannula) The aggregate score is reflective of the participants status.

Time frame:
Day 10
Reported as:
Number · percentage of participants
Percentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline
percentage of participantsPlacebo + SOCBaricitinib + SOC
Percentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline52.5 (46.7 to 58.2)56.7 (50.9 to 62.4)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Regression, Logistic · p = 0.4290 · Odds ratio (or): 1.15 · 95% CI 0.81 to 1.63
SecondaryOverall Mortality

Number of deaths by Day 28.

Time frame:
Day 1 to Day 28
Reported as:
Number · event of death
Overall Mortality
event of deathPlacebo + SOCBaricitinib + SOC
Overall Mortality10465
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Log Rank · p = 0.0018 · Hazard ratio (hr): 0.57 · 95% CI 0.41 to 0.78
SecondaryDuration of Stay in the Intensive Care Unit (ICU) in Days

Duration of stay in the ICU in days.

Time frame:
Day 1 to Day 28
Reported as:
Least squares mean · days
Duration of Stay in the Intensive Care Unit (ICU) in Days
daysPlacebo + SOCBaricitinib + SOC
Duration of Stay in the Intensive Care Unit (ICU) in Days3.17 ± 0.3133.19 ± 0.315
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · ANOVA · p = 0.9526 · Ls mean difference (net): 0.02 · 95% CI -0.62 to 0.65
SecondaryTime to Clinical Deterioration (One-category Increase on the NIAID-OS)

The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. A higher score is representative of worse clinical outcome with a score of 8 being the highest and representing death.

Time frame:
Day 1 to Day 28
Reported as:
Median · days
Time to Clinical Deterioration (One-category Increase on the NIAID-OS)
daysPlacebo + SOCBaricitinib + SOC
Time to Clinical Deterioration (One-category Increase on the NIAID-OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Log Rank · p = 0.1831 · Hazard ratio (hr): 0.887 · 95% CI 0.741 to 1.061
SecondaryTime to Resolution of Fever in Participants With Fever at Baseline

Time to resolution of fever in participants with fever at baseline was calculated using cox proportional hazard regression model adjusted for baseline disease severity (OS 4, OS 5, OS 6), age (\<65 years, \>=65 years), region (United States, Europe, rest of world), and systemic corticosteroids used at baseline for primary study condition (Yes/No).

Time frame:
Day 1 to Day 28
Reported as:
Median · days
Time to Resolution of Fever in Participants With Fever at Baseline
daysPlacebo + SOCBaricitinib + SOC
Time to Resolution of Fever in Participants With Fever at Baseline4.00 (3.00 to 4.00)3.00 (3.00 to 4.00)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Log Rank · p = 0.0243 · Hazard ratio (hr): 1.202 · 95% CI 1.017 to 1.421
SecondaryMean Change From Baseline on the National Early Warning Score (NEWS)

The NEWS score is used to detect and report changes in illness severity in participants with acute illness to identify participants at risk for poor outcomes. The score is based on six physiological parameters (Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness). A score is assigned to each parameter, and the sum of the score represents the participant's risk of poor outcomes with a minimum score of 0 representing the better outcome, a score of 7 or greater reflects high clinical risk for worsening and maximum score of 19 representing the worse outcome.

Time frame:
Baseline, Day 4; Baseline, Day 7; Baseline, Day 10; Baseline, Day 14
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline on the National Early Warning Score (NEWS)
score on a scalePlacebo + SOCBaricitinib + SOC
Day 4-0.59 ± 0.127-0.76 ± 0.125
Day 7-0.86 ± 0.145-1.04 ± 0.143
Day 10-1.33 ± 0.160-1.45 ± 0.158
Day 14-1.41 ± 0.183-1.66 ± 0.182
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Mixed Models Analysis · p = 0.191 · Ls mean difference (final values): -0.17 · 95% CI -0.42 to 0.08
  • Placebo + SOC vs Baricitinib + SOC · Mixed Models Analysis · p = 0.278 · Ls mean difference (final values): -0.17 · 95% CI -0.49 to 0.14
  • Placebo + SOC vs Baricitinib + SOC · Mixed Models Analysis · p = 0.496 · Ls mean difference (final values): -0.13 · 95% CI -0.49 to 0.24
  • Placebo + SOC vs Baricitinib + SOC · Mixed Models Analysis · p = 0.263 · Ls mean difference (final values): -0.25 · 95% CI -0.70 to 0.19
SecondaryTime to Definitive Extubation

Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.

Time frame:
Day 1 to Day 28
Reported as:
Median · days
Time to Definitive Extubation
daysPlacebo + SOCBaricitinib + SOC
Time to Definitive ExtubationNA (NA to NA)NA (NA to NA)
SecondaryTime to Independence From Non-Invasive Mechanical Ventilation

Time to independence from non-invasive mechanical ventilation was measured in days among participants who required non-invasive ventilation.

Time frame:
Day 1 to Day 28
Reported as:
Median · days
Time to Independence From Non-Invasive Mechanical Ventilation
daysPlacebo + SOCBaricitinib + SOC
Time to Independence From Non-Invasive Mechanical Ventilation11.00 (9.00 to 13.00)12.00 (9.00 to 14.00)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Log Rank · p = 0.6436 · Hazard ratio (hr): 1.090
SecondaryTime to Independence From Oxygen Therapy in Days

Time to independence from oxygen therapy in days.

Time frame:
Day 1 to Day 28
Reported as:
Median · days
Time to Independence From Oxygen Therapy in Days
daysPlacebo + SOCBaricitinib + SOC
Time to Independence From Oxygen Therapy in Days8.00 (8.00 to 9.00)8.00 (7.00 to 8.00)
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · Log Rank · p = 0.1270 · Hazard ratio (hr): 1.124
SecondaryNumber of Days With Supplemental Oxygen Use

Number of days with supplemental oxygen use.

Time frame:
Day 1 to Day 28
Reported as:
Least squares mean · days
Number of Days With Supplemental Oxygen Use
daysPlacebo + SOCBaricitinib + SOC
Number of Days With Supplemental Oxygen Use4.60 ± 0.2214.37 ± 0.222
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · ANOVA · p = 0.3058 · Ls mean difference (net): -0.23 · 95% CI -0.68 to 0.21
SecondaryNumber of Days of Resting Respiratory Rate <24 Breaths Per Minute

Number of days of resting respiratory rate \<24 breaths per minute.

Time frame:
Day 1 to Day 28
Reported as:
Least squares mean · days
Number of Days of Resting Respiratory Rate <24 Breaths Per Minute
daysPlacebo + SOCBaricitinib + SOC
Number of Days of Resting Respiratory Rate <24 Breaths Per Minute9.62 ± 0.3009.73 ± 0.304
Statistical analysis
  • Placebo + SOC vs Baricitinib + SOC · ANOVA · p = 0.7073 · Ls mean difference (net): 0.11 · 95% CI -0.49 to 0.72

Adverse events

Collected over Baseline up to 119 days Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo104/752 (13.8%)135/752 (18%)0/752 (0%)
4 Milligrams (mg) Baricitinib65/750 (8.7%)110/750 (14.7%)0/750 (0%)
Placebo Follow-up16/613 (2.6%)12/613 (2%)0/613 (0%)
4mg Baricitinib Follow-up18/645 (2.8%)18/645 (2.8%)0/645 (0%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventPlacebo4 Milligrams (mg) BaricitinibPlacebo Follow-up4mg Baricitinib Follow-up
Acute respiratory failureRespiratory, thoracic and mediastinal disorders29/75217/7501/6132/645
Septic shockInfections and infestations24/75213/7504/6135/645
Covid-19 pneumoniaInfections and infestations21/75221/7500/6130/645
Respiratory failureRespiratory, thoracic and mediastinal disorders17/75210/7500/6131/645
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/75212/7500/6130/645
Covid-19Infections and infestations10/7528/7501/6131/645
PneumoniaInfections and infestations10/7528/7500/6131/645
Acute kidney injuryRenal and urinary disorders10/7527/7501/6130/645
PneumothoraxRespiratory, thoracic and mediastinal disorders2/7526/7500/6130/645
Cardio-respiratory arrestCardiac disorders6/7523/7501/6131/645

Baseline characteristics

All participants randomly assigned to study intervention. Participants were analyzed according to the intervention to which they were assigned.

Age, Continuous
Age, Continuous(years)Placebo +SOCBaricitinib + SOCTotal
Mean57.5 ± 13.857.8 ± 14.357.6 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo +SOCBaricitinib + SOCTotal
Female288274562
Male473490963
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo +SOCBaricitinib + SOCTotal
American Indian or Alaska Native168148316
Asian9480174
Native Hawaiian or Other Pacific Islander235
Black or African American363975
White440480920
More than one race123
Unknown or Not Reported201232
Region of Enrollment
Region of Enrollment(Participants)Placebo +SOCBaricitinib + SOCTotal
Puerto Rico3811
Argentina101107208
United States155154309
Japan191938
United Kingdom7411
India311950
Russia5458112
Spain424587
South Korea201636
Brazil165172337
Mexico143138281
Italy101525
Germany11920
08

Study locations

96 sites
  • Dignity Health Mercy Gilbert Medical Center
    Gilbert, Arizona 85297, United States
  • Valleywise Health
    Phoenix, Arizona 85008, United States
  • St Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • San Francisco VA Medical Center
    San Francisco, California 94121, United States
  • Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • Holy Cross Hospital Inc.
    Fort Lauderdale, Florida 33308, United States
  • Westchester General Hospital
    Miami, Florida 33155, United States
  • Grady Health System
    Atlanta, Georgia 30303, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Parkview Regional Medical Center
    Fort Wayne, Indiana 46845, United States
  • Community Hospital South
    Indianapolis, Indiana 46227, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • South Shore Hospital
    Weymouth, Massachusetts 02190, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Renown Regional Med. Center
    Reno, Nevada 89502, United States
  • SUNY Downstate
    Brooklyn, New York 11203, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • OSU Med Intl Med Houston Ctr
    Tulsa, Oklahoma 74127, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Temple Univ School of Med
    Philadelphia, Pennsylvania 19140, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • MultiCare Good Samaritan Hospital
    Tacoma, Washington 98405, United States
  • Sanatorio Sagrado Corazón
    Ciudad de Buenos Aires, AR C1039AAC, Argentina
  • ClÃ-nica Zabala
    Ciudad de Buenos Aires, AR C1426AAM, Argentina
  • Hospital Z.G.A.D "Evita Pueblo"
    Berazategui, Buenos Aires 1884, Argentina
  • Sanatorio de la Trinidad Mitre
    Caba, Buenos Aires C1039AAO, Argentina
  • Fundacion Sanatorio Guemes
    Caba, Buenos Aires C1180AAX, Argentina
  • Casa Hospital San Juan de Dios
    Ramos Mejía, Buenos Aires 1704, Argentina
  • Hospital Interzonal General de Agudos "Eva Peron"
    San Martin, Buenos Aires B1650 NBN, Argentina
  • Clinica Adventista Belgrano
    Caba, Ciudad Autónoma De Buenos Aire C1430EGF, Argentina
  • Clinica Central S.A.
    Villa Regina, Rio Negro R8336, Argentina
  • Clinica Viedma
    Viedma, Río Negro 8500, Argentina
  • Hospital San Roque
    Cordoba, 5000, Argentina
  • Hospital Felício Rocho
    Belo Horizonte, Minas Gerais 30110-934, Brazil
  • Centro Hospitalar de Reabilitacao Ana Carolina Moura Xavier
    Curitiba, Parana 80035-090, Brazil
  • CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva
    Curitiba, Paraná 82530-200, Brazil
  • CPCLIN
    Natal, Rio Grande Do Norte 59025-050, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, RS 90035-903, Brazil
  • Hospital Carlos Fernando Malzoni Matao
    Matao, Sao Paulo 15990-060, Brazil
  • Pesquisare
    Santo Andre, Sao Paulo 09080-110, Brazil
  • Praxis Pesquisa Medica
    Santo André, Sao Paulo 09090-790, Brazil
  • Faculdade de Medicina do ABC
    Santo Andre, SP 09060-870, Brazil
  • Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP
    Botucatu, São Paulo 18618-687, Brazil
  • IPECC - Instituto de Pesquisa Clinica de Campinas
    Campinas, São Paulo 13060-080, Brazil
  • Hospital PUC-CAMPINAS
    Campinas, São Paulo 13060-904, Brazil
  • CECIP - Centro de Estudos do Interior Paulista
    Jaú, São Paulo 17201-130, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Real e Benemerita Associação Portuguesa de Beneficiencia
    São Paulo, 01323-900, Brazil
  • Hospital Alemão Oswaldo Cruz
    São Paulo, 01327-001, Brazil
  • Universidade Federal de São Paulo - Escola Paulista de Medicina
    São Paulo, 04037-002, Brazil
  • Hospital Santa Paula
    São Paulo, 04556-100, Brazil
  • Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica
    São Paulo, 08270-120, Brazil
  • Universitätsklinikum Erlangen
    Erlangen, Bayern 91054, Germany
  • Klinikum Rechts der Isar der TU München
    München, Bayern 81675, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Schleswig-Holstein 24105, Germany
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09116, Germany
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110060, India
  • Unity Hospital
    Surat, Gujarat 395010, India
  • Medanta-The Medicity
    Gurgaon, Haryana 122001, India
  • Government Medical College (GMC) Aurangabad
    Aurangabad, Maharashtra 431001, India
  • Government Medical College
    Nagpur, Maharashtra 440003, India
  • Ruby Hall Clinic and Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • Medica Superspecialty Hospital
    Kolkata, West Bengal 700099, India
  • Aakash Healthcare Super Speciality Hospital
    New Delhi, 110075, India
  • INMI Lazzaro Spallanzani
    Roma, Rome 00149, Italy
  • Ospedale Niguarda Ca Granda
    Milano, 20162, Italy
  • Nuovo Ospedale di Prato S. Stefano
    Prato, 59100, Italy
  • Yokohama Municipal Citizen's Hospital
    Yokohama, Kanagawa 2210855, Japan
  • Edogawa Medicare Hospital
    Edagawa, Tokyo 133 0071, Japan
  • Tokyo Medical University Hachioji Medical Center
    Hachioji, Tokyo 193-0998, Japan
  • Korea University Ansan Hospital
    Ansan-si, Gyeonggi-do 15355, Korea, Republic of
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, Korea, Republic of
  • Seoul National University Boramae Medical Center
    Seoul, Seoul, Korea 07061, Korea, Republic of
  • Seoul Medical Center
    Seoul, 02053, Korea, Republic of
  • Instituto Nacional de Cardiologia Ignacio Chavez
    Mexico, DF 14080, Mexico
  • Instituto Nacional de Enfermedades Respiratorias
    Mexico, DF 14080, Mexico
  • Instituto Nacional de Cancerologia
    Mexico City, FD 14080, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutrici Salva Zubir
    Mexico City, Federal District 14080, Mexico
  • Hospital General Agustín O'Horán
    Yucatan, Merida 97000, Mexico
  • ITESM Campus Monterrey
    Monterrey, Nuevo Leon 64710, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo León 64460, Mexico
  • Advanced Clinical Research, LLC
    Bayamon, 00961, Puerto Rico
  • City Clinical Hospital #15 named after O.M. Filatov
    Moscow, 111539, Russian Federation
  • First Moscow State Medical University n.a. Sechenov
    Moscow, 119991, Russian Federation
  • Saint-Petersburg City Pokrovskaya Hospital
    Saint-Petersburg, 199106, Russian Federation
  • Hospital Txagorritxu
    Vitoria, Alava 01009, Spain
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Hospital Universitario Infanta Leonor-INTERNAL MED
    Madrid, 28031, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • The Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Barnet Hospital
    Barnet, Herts EN5 3DJ, United Kingdom
  • St. George's University Hospitals NHS Foundation Trust
    London, SW17 0QT, United Kingdom
09

References and documents

Publications

  • Kramer A, Prinz C, Fichtner F, Fischer AL, Thieme V, Grundeis F, Spagl M, Seeber C, Piechotta V, Metzendorf MI, Golinski M, Moerer O, Stephani C, Mikolajewska A, Kluge S, Stegemann M, Laudi S, Skoetz N. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209. PubMed 35695334 ↗
  • Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC; COV-BARRIER Study Group. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Apr;10(4):327-336. doi: 10.1016/S2213-2600(22)00006-6. Epub 2022 Feb 3. Erratum In: Lancet Respir Med. 2022 Apr;10(4):e43. doi: 10.1016/S2213-2600(22)00057-1. PubMed 35123660 ↗
  • Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1. Erratum In: Lancet Respir Med. 2021 Oct;9(10):e102. doi: 10.1016/S2213-2600(21)00410-0. PubMed 34480861 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting

Access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2021, 8 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2020
First posted
Jun 9, 2020
StartActual
Jun 12, 2020
Primary completionActual
Feb 12, 2021
CompletionActual
Jun 10, 2021
Results first posted
Mar 24, 2022
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04421027
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Jun 12, 2020
Primary completion
Feb 12, 2021
Completion
Jun 10, 2021
Results posted
Mar 24, 2022
Last update
Jul 28, 2022

Study contacts

Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion